Compare BridgeBio Pharma Inc (BBIO) vs iShares 7-10 Year Treasury Bond ETF (IEF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs iShares 7-10 Year Treasury Bond ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while iShares 7-10 Year Treasury Bond ETF trades at $92.9. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | IEF | |
|---|---|---|
Market Cap | $16.61B | — |
Sector | Health | — |
52-Week High | $90.17 | $97.99 |
52-Week Low | $47.29 | $92.76 |
Enterprise Value | $18.16B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
IEF (iShares 7-10 Year Treasury Bond ETF) trades at $93.17 with minimal daily movement (+0.24%). Technical indicators show a neutral to bearish bias with moving averages signaling caution. The ETF maintains consistent dividend distributions, with recent payments of $0.31-$0.32 per share. Market focus remains on Treasury yield movements influenced by inflation data and Middle East tensions affecting oil prices.
Outlook remains tied to interest rate expectations and inflation trends. Recent institutional accumulation by Bank of America and Ferguson Shapiro provides support, but rising Treasury yields pose headwinds. Key risks include Federal Reserve policy shifts and geopolitical volatility impacting bond markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →
